Recognising Immune-Related Adverse Events: Module 3 of OncoDaily Academy’s Six-Part Programme on Immune Checkpoint Inhibitors

Recognising Immune-Related Adverse Events: Module 3 of OncoDaily Academy’s Six-Part Programme on Immune Checkpoint Inhibitors

Immune checkpoint inhibitors can produce toxicities that look very different from those associated with conventional chemotherapy. They may appear subtly, involve almost any organ system, and sometimes emerge even after treatment has stopped.

A symptom that seems minor in a typical oncology setting can therefore require a very different level of attention in a patient receiving immunotherapy.

Module 3 of OncoDaily Academy’s six-part programme on immune checkpoint inhibitors focuses on recognising immune-related adverse events (irAEs) early, identifying clinical red flags and understanding when symptoms require escalation.

OncoDaily Academy is now live. Register for FREE and create your account today.

OncoDaily Academy

Why Immune-Related Toxicity Requires a Different Approach

Immune checkpoints normally help regulate immune activity and protect healthy tissues from excessive inflammation. Blocking these pathways can strengthen antitumour immunity, but it can also disrupt immune tolerance and lead to inflammation or dysfunction in normal tissues.

Unlike many chemotherapy toxicities, irAEs do not necessarily follow a predictable treatment-cycle pattern. They can develop early, emerge after several months, or become apparent after immunotherapy has ended.

Module 3 explores why this difference matters in clinical practice and why recognising a possible irAE requires more than simply asking whether a symptom is severe.

Learners will consider the importance of symptom trajectory, changes from a patient’s own baseline and the possibility that apparently non-specific complaints may represent emerging immune-mediated toxicity.

Recognising the Signals That Matter

The module moves from the underlying biology of irAEs to how they can present across different organ systems.

Rather than attempting to memorise every possible toxicity, learners are encouraged to develop a structured approach to assessment: identifying new or worsening symptoms, looking for red flags, comparing findings with baseline and considering immune-mediated toxicity alongside other possible diagnoses.

The course also connects back to Module 2 by considering how next-generation checkpoint inhibitor designs may influence toxicity. New targets and antibody designs may alter safety profiles, but they do not remove the need to recognise the established patterns of immune-related adverse events.

An important message throughout the module is that a theoretically more selective therapy should not automatically be assumed to be safer without clinical evidence.

What to Expect from Module 3

Module 3 will help clinicians recognise common presentations of immune-related toxicity and identify features that may require urgent assessment.

Learners will work through clinical scenarios involving different organ systems, consider how toxicity severity is assessed, and practise distinguishing potentially important immune-mediated symptoms from other causes commonly encountered in cancer care.

The module also introduces a structured pre-cycle toxicity screen, designed to help clinicians identify changes that patients may minimise, overlook or not realise could be related to treatment.

Interactive cases encourage learners to move beyond the symptom a patient initially reports and ask the questions needed to understand its severity, trajectory and clinical significance.

From Recognition to Management

Module 3 focuses on the first stages of the irAE pathway: recognising possible toxicity, carrying out an initial assessment and identifying when escalation is required.

This prepares learners for the next stage of the programme, where the focus will move from recognising immune-related adverse events to their management.

About OncoDaily Academy

The immuno-oncology programme is the first educational initiative from OncoDaily Academy, a global platform created to connect clinicians with accessible, clinically relevant and expert-led learning across the evolving landscape of cancer care.

The Academy is developed by OncoDaily in collaboration with The Learning Lab, a digital education spin-out of Guy’s and St Thomas’ NHS Foundation Trust, working with Guy’s Cancer Academy.

The aim is to make specialist oncology education more accessible while helping clinicians navigate a field in which new biomarkers, therapies and treatment combinations are continuously reshaping clinical practice.

This programme is independent medical education. Agenus has provided non-promotional funding and support. Editorial control of all educational content remains with the clinical and educational team.

It is intended for clinicians across the cancer workforce, including oncologists, trainees and nurses. The programme is free to access online. Participants receive a free certificate of completion from Guy’s Cancer Academy after each individual module, as well as an additional certificate after completing the full six-part programme.

Registration is free: Create your OncoDaily Academy account now!

Explore Module 2 of OncoDaily Academy’s six-part programme on immune checkpoint inhibitors.

OncoDaily Academy

Nare Hovhannisyan
Fact checked by Nare Hovhannisyan MD, Medical Writer
Aren Petrosyan
Medically reviewed by Aren Petrosyan MD, Editor at OncoDaily and Rankings and Analytics Lead of BIGR